Short Interest in enGene Holdings Inc. (NASDAQ:ENGNW) Increases By 122.2%

enGene Holdings Inc. (NASDAQ:ENGNW) was the target of a large growth in short interest in October. As of October 15th, there was short interest totaling 10,000 shares, a growth of 122.2% from the September 30th total of 4,500 shares. Based on an average daily volume of 12,900 shares, the short-interest ratio is presently 0.8 days. Based on an average daily volume of 12,900 shares, the short-interest ratio is presently 0.8 days.

enGene Trading Down 11.9%

Shares of enGene stock opened at $2.08 on Friday. The business’s fifty day simple moving average is $1.18 and its 200 day simple moving average is $0.92. enGene has a 12 month low of $0.51 and a 12 month high of $3.80.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.